#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Stephen Machatha Email
Chief Development Officer . Aldeyra Therandshy;aandshy;peuandshy;tics
Lexington,
LocationPrimary Email
How to contact Stephen Machatha
Join and see Stephen's contact info for free!Phone
Current Roles
Employees:
23Revenue:
$3.6MAbout
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.Aldeyra Therandshy;aandshy;peuandshy;tics Address
131 Hartwell AvenueLexington, null